Treats serious infections due to susceptible strains of Gram-negative bacteria, including…. ANDA 205604, held by Fresenius Kabi USA. Amikacin Sulfate.
As of Nov 16, 2026, ANDA 205604 (Amikacin Sulfate), held by Fresenius Kabi USA, was first approved by FDA on Dec 9, 2015, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Amikacin sulfate injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella species, Enterobacter species, Serratia species, and Acinetobacter species. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 9, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Amikacin SulfateEQ 250MG BASE/ML · injectable;injection | Amikacin Sulfate | Rx |
| Aug 28, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 10, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 10, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 10, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 9, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters